Companies › Molecure
2 active drug programs in 2 registered trials: 1 Phase 1, 1 Phase 2; Oncology, Immunology; next expected readout Mar 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| OATD-01 Chitinase-1 (CHIT1) inhibitor | CHIT1 | Phase 2 | Pulmonary Sarcoidosis | Aug 2027 |
| OATD-02 Arginosuccinate synthetase 1 (ASS1) restoration or arginine level enhancement | – | Phase 1 | Advanced Ovarian Carcinoma | Mar 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05759923 | OATD-02 | Phase 1 | Advanced Ovarian Carcinoma | Oncology | Mar 2027 |
| NCT06205121 | OATD-01 | Phase 2 | Pulmonary Sarcoidosis | Immunology | Aug 2027 |
–
Telios Pharma Tavotek Biotherapeutics Xizang Haisco Pharmaceutical Ganzhou Hemay Pharmaceutical Antengene Biologics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.